This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CBT-502

CBT Pharmaceuticals

Drug Names(s): CBT-502

Description: CBT-502 is a novel IgG4 humanized monoclonal antibody against the Programmable Death Ligand-1 (PDL-1) membrane receptor on tumor cells.

Deal Structure: CBT and Chia Tai TianQing (CTTQ)
World-wide rights were granted to CBT Pharmaceuticals and China rights granted to Chia Tai TianQing (CTTQ). No additional details were released.

Partners: Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.


CBT-502 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug